display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)metastatic/advanced RCC (mRCC) - 1st line (L1)metastatic/advanced RCC (mRCC) - 2nd line (L2)
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)metastatic/advanced RCC (mRCC) - 1st line (L1)mRCC - L1 - PDL1 negativemRCC - L1 - PDL1 positivemetastatic/advanced RCC (mRCC) - 2nd line (L2)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone IMmotion-010 IMmotion-150 ... IMmotion-150 ...
atezolizumab plus bevacizumab IMmotion-150 ... IMmotion-151 ... IMmotion-151 ... IMmotion-150 ... IMmotion-151 ...
avelumab based treatment
avelumab plus axitinib JAVELIN Renal 101 ... JAVELIN Renal 101...
nivolumab based treatment
nivolumab alone CheckMate 914 CheckMate 025
nivolumab plus cabozantinib CheckMate 9ER
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-564
pembrolizumab plus axitinib KEYNOTE-426
pembrolizumab plus lenvatinib KEYNOTE-581/CLEAR ...
Immune checkpoint association
nivolumab plus ipilimumab CheckMate 214 ... CheckMate 214 ... CheckMate 214 ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons